A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis

NCT07551427 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: TQ05105 Tablets (Rovadicitinib Tablets)

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.